<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902200</url>
  </required_header>
  <id_info>
    <org_study_id>AR-12286-CS201</org_study_id>
    <nct_id>NCT00902200</nct_id>
  </id_info>
  <brief_title>A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)</brief_title>
  <official_title>A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in Patients With Elevated Intraocular Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized to receive AR-12286 Ophthalmic Solution 0.05%, 0.1%, and 0.25% or&#xD;
      its vehicle (one eye), q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days. The&#xD;
      first dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy&#xD;
      will be evaluated in the clinic throughout this period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint will be mean diurnal IOP on each day at which diurnal IOP is measured at each timepoint.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Elevated Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-12286 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-12286 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-12286 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-12286</intervention_name>
    <description>See arms</description>
    <arm_group_label>AR-12286 0.05%</arm_group_label>
    <arm_group_label>AR-12286 0.1%</arm_group_label>
    <arm_group_label>AR-12286 0.25%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-12286 vehicle</intervention_name>
    <description>See arms</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or greater.&#xD;
&#xD;
          2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT). Unmedicated&#xD;
             (post-washout, if required) IOP &gt;= 24 mm Hg in one or both eyes at 08:00 hours, &gt;= 21&#xD;
             mm Hg at 10:00, 12:00 and 16:00 hours on post-washout measurement (Visit 1).&#xD;
&#xD;
          3. Corrected visual acuity in each eye +1.0 logMAR (logarithm mininum angle of&#xD;
             resolution) or better by ETDRS (Early Treatment Diabetic Retinopathy Study) in each&#xD;
             eye (equivalent to 20/200).&#xD;
&#xD;
          4. Able and willing to give signed informed consent and follow study instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Either eye&#xD;
&#xD;
          1. Intraocular pressure &gt; 36 mm Hg&#xD;
&#xD;
          2. Known hypersensitivity to any component of the formulation or to topical anesthetics,&#xD;
             (benzalkonium chloride, etc.)&#xD;
&#xD;
          3. Ocular trauma within the past six months, or ocular surgery or laser treatment within&#xD;
             the past three months.&#xD;
&#xD;
          4. History or evidence of ocular infection inflammation, or of herpes simplex keratitis,&#xD;
             or clinically significant blepharitis or conjunctivitis at baseline (Visit 1)..&#xD;
&#xD;
          5. Contact lens wear within 30 minutes of instillation of study medication.&#xD;
&#xD;
          6. Ocular medication of any kind within 30 days of Visit 2, with the exception of a)&#xD;
             ocular hypotensive medications (which must be washed out according to the provided&#xD;
             schedule), b) lid scrubs (which may be used prior to, but not after Visit 2) or c)&#xD;
             lubricating drops for dry eye (which may be used throughout the study),&#xD;
&#xD;
          7. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe&#xD;
             keratoconjunctivitis sicca) which might interfere with the study, including&#xD;
             glaucomatous damage so severe that washout of ocular hypotensive medications for one&#xD;
             month is not judged safe (i.e., cup-disc ratio &gt; 0.8).&#xD;
&#xD;
          8. Central corneal thickness greater than 600 microns.&#xD;
&#xD;
          9. Any abnormality preventing reliable applanation tonometry.&#xD;
&#xD;
             Study eye:&#xD;
&#xD;
         10. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure.&#xD;
&#xD;
             Note: Previous laser peripheral iridotomy is acceptable.&#xD;
&#xD;
         11. Previous glaucoma intraocular surgery or laser procedures in study eye(s).&#xD;
&#xD;
         12. Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK (photorefractive&#xD;
             keratectomy), LASIK (Laser-Assisted in situ Keratomileusis), etc.).&#xD;
&#xD;
             General/Systemic:&#xD;
&#xD;
         13. Clinically significant abnormalities in laboratory tests at screening (See Appendix&#xD;
             1).&#xD;
&#xD;
         14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia&#xD;
             gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere&#xD;
             with the study.&#xD;
&#xD;
         15. Participation in any investigational study within the past 30 days.&#xD;
&#xD;
         16. Changes of systemic medication during the study that could have a substantial effect&#xD;
             on IOP within 30 days prior to screening, or anticipated during the study.&#xD;
&#xD;
         17. Due to status of preclinical safety program, women of childbearing potential who are&#xD;
             pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of&#xD;
             birth control. An adult woman is considered to be of childbearing potential unless she&#xD;
             is one year post-menopausal or three months post-surgical sterilization. All females&#xD;
             of childbearing potential must have a negative urine pregnancy test result at the&#xD;
             screening examination and must not intend to become pregnant during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom van Haarlem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soilsh Practice</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacharach practice</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hernando Eye Institute</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taustine Eye Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mundorf Practice</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <disposition_first_submitted>February 17, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 21, 2014</disposition_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

